Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections

Launched by INDIANA UNIVERSITY · May 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying two antibiotics, trimethoprim-sulfamethoxazole (TMP-SMX) and clindamycin, to see which one works better for treating serious infections in children caused by a bacteria called MRSA, which is resistant to many antibiotics. The researchers want to find out if TMP-SMX is effective and safe for children with these infections, which can affect bones, joints, and other areas of the body.

To participate, children between the ages of 60 days and 18 years who have been diagnosed with an MRSA infection and are ready to switch to oral antibiotics may be eligible. Participants will take either TMP-SMX or clindamycin and keep a diary to track their symptoms and any side effects they experience. It's important to know that this trial is not yet recruiting participants, and there are specific health conditions that could prevent someone from participating. Overall, the goal is to improve treatment options for children facing these challenging infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 60 days to 18 years of age (inclusive) at the time of oral step down treatment
• 2. Diagnosed by the clinical team with OAI or HNI:
• • OAI- at least 1 focal finding and 1 systemic finding OR radiographic confirmation of OAI
• • Focal finding- pain/swelling over a bone/joint, or restricted movement/failure to bear weight
• • Systemic finding- fever \>38oC, or elevated c-reactive protein (CRP) or elevated erythrocyte sedimentation rate. (ESR) or elevated white blood cell count (WBC) or elevated WBC in synovial fluid OR
• • Radiographic confirmation- findings consistent with osteomyelitis or septic arthritis - Plain radiograph, MRI, CT or ultrasound, bone scan result indicating abnormal bone, subperiosteal or bone marrow findings consistent with infection
• • HNI- at least 1 focal finding and 1 systemic finding OR radiographic confirmation of HNI
• • Focal finding- facial pain or redness, eye pain or proptosis, neck or throat pain or swelling, ear pain or proptosis
• • Systemic finding- fever \>38oC, or elevated CRP or elevated ESR or elevated WBC OR
• • Radiographic confirmation- findings consistent with facial/orbital cellulitis, cervical lymphadenitis, mastoiditis, or deep neck infection/abscess (including peritonsillar, retro- and para-pharyngeal. Plain radiograph, MRI, CT or ultrasound, bone scan result indicating abnormal findings consistent with infection
• • 3. Treated by the clinical team for confirmed MRSA or suspected MRSA infection
• • Confirmed MRSA- positive culture for MRSA from a sterile body fluid (e.g., blood, abscess, bone, synovial fluid, or other surgical specimen)
• • Suspected MRSA- treatment for MRSA by the clinical team without microbiologic confirmation (e.g., negative cultures)
• • 4. Currently ready or planned to be transitioned to oral antibiotic therapy by the clinical team
• • 5. OAI or HNI symptoms \< 14 days at the time of hospital admission
• Exclusion Criteria:
• • 1. Enrollment in another interventional study or receipt of investigational drug as part of a research trial within the past 30 days.
• • 2. Known cancer, acquired or primary (including sickle cell anemia or G6PD deficiency) immunodeficiency
• • 3. Underlying bone disease, presence of hardware /implantable device in affected bone/joint
• • 4. Infection (OAI or HNI) resulting from penetrating wounds, open fractures, major trauma, foreign body or post-operative infection.
• • 5. Spinal osteomyelitis
• • 6. Underlying chronic renal, gastrointestinal, liver, or heart disease that would be expected to potentially affect absorption or the metabolism of assigned drug
• • 7. Inability to take medicine by mouth, gastrostomy, jejunostomy or nasogastric tube
• • 8. Received intravenous antibiotic therapy as the treatment for OAI or HNI \>14 days.
• • 9. Inability or unwilling to consent
• • 10. Any social or medical conditions judged by the study clinician to preclude participation because it could negatively affect the participant.
• • 11. Allergy to both TMP-SMX and clindamycin
• • 12. Known MRSA isolate resistant to both TMP-SMX and clindamycin
• • 13. Patient is known to be pregnant at the time of enrollment